Bristol-Meyers Squibb recalls injectable Coumadin

Bristol-Meyers Squibb issued a voluntary recall of Coumadin for injection after particulate matter was found in unreleased samples.

The company said the recall is precautionary and involves few lots. Oral Coumadin (Coumadin tablets) is not affected by this recall.

Injection of particulate matter can cause fatal adverse reactions, including embolism. Bristol-Meyers Squibb has advised discontinued use for any injectable Coumadin that is part of the affected lots distributed to hospitals and pharmacies between November 2011 and January 2014.

Effected six lots of COUMADIN FOR INJECTION (warfarin sodium) 5 mg single-use vials include 201125, 210026, 201127, 201228, 201229, and 201230 with expiration dates from September 2014 through September 2015.

Physicians and providers can contact Bristol-Meyer Squibb’s recall vendor GENCO to return affected lots.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.